Condition

Drug Toxicity

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials8

Recruiting0

Common interventions11

Lead sponsors shown8

Clinical trials

8 shown

Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After LobectomyNCT05472350 · 2022-08-01

UNKNOWN

Evaluation of MyoStrain™ in Clinical PracticeNCT03825224 · 2019-04-15

COMPLETED

Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer PatientsNCT03469063 · 2018-06-28

UNKNOWN

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin TreatmentNCT02864030 · 2014-05-01

COMPLETED

Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male SubjectsNCT01979380 · 2013-12-01

COMPLETED

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIsNCT01965275 · 2013-10-01

UNKNOWN

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast CancerNCT00090844 · 2004-07-01

TERMINATED

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung CancerNCT00002586 · 1993-01-01

COMPLETED

Common interventions

13-cis retinoic acidDRUG1 AferBioDIETARY_SUPPLEMENT1 Breztri AerosphereDRUG1 Diagnostic Test: MyostrainPROCEDURE1 ERIBULIN MESYLATEDRUG1 Erlotinib or GefitinibDRUG1 KD101DRUG1 placeboDRUG1 PlaceboOTHER1 TocopherolDIETARY_SUPPLEMENT1 triptorelinDRUG1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

eribulin mesylate1 isotretinoin1 placebo1 triptorelin1

Leading sponsors

Anhui Medical University 1 Barretos Cancer Hospital 1 Jianxing He 1 Kwang Dong Pharmaceutical co., ltd. 1 Oncologia Medica dell'Ospedale Fatebenefratelli 1 University of Colorado, Denver 1 University of Kansas Medical Center 1 University of South Florida 1

Trial status mix

COMPLETED4

UNKNOWN3

TERMINATED1

Phase mix

PHASE23

NA2

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.